Anlotib 12 mg, marketed under the brand name Anlotib, is an innovative oral anticancer agent developed for the treatment of advanced solid tumors. As a multi-targeted tyrosine kinase inhibitor (TKI), Anlotib is designed to interfere with multiple signaling pathways involved in tumor growth and angiogenesis, offering a comprehensive approach to cancer therapy. It represents a significant advancement in oncology, providing patients with new hope in managing challenging malignancies.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

Tyrosine Kinase Inhibitor (Anti-neoplastic Agent)

Indications

Anlotib 12 mg is indicated for the treatment of patients with:

• Advanced or metastatic non-small cell lung cancer (NSCLC) after prior therapy

• Soft tissue sarcoma (STS) that is unresectable or metastatic

• Other solid tumors where a multi-targeted tyrosine kinase inhibition strategy may provide clinical benefit

The therapy should be initiated and supervised by oncology specialists experienced in targeted cancer treatments.

Pharmacology

Anlotinib is a small-molecule tyrosine kinase inhibitor that targets multiple receptors, including VEGFR 1–3, FGFR 1–4, PDGFR α/β, c-Kit, and Ret. These receptors play a critical role in tumor angiogenesis, proliferation, and survival. By inhibiting these pathways, Anlotib reduces tumor vascularization, blocks abnormal signaling, and slows tumor growth.

Preclinical studies have shown that Anlotib:

• Inhibits endothelial cell proliferation and migration

• Reduces microvessel density in tumor tissue

• Suppresses tumor growth in various xenograft models

Anlotib’s multi-targeted activity makes it effective against tumors that are resistant to single-pathway inhibitors. Following oral administration, Anlotib demonstrates adequate absorption, with steady-state plasma concentrations achieved after repeated daily dosing. It is metabolized in the liver and eliminated primarily through feces.

Dosage & Administration

• Recommended dose: 12 mg orally, once daily for 14 consecutive days, followed by 7 days off (21-day cycle)

• Tablets should be taken at the same time each day and swallowed whole with water

• May be taken with or without food

• Dose adjustments may be necessary based on tolerability and adverse reactions, including hypertension, hand-foot syndrome, or liver enzyme elevations

• Treatment should continue until disease progression or unacceptable toxicity

Side Effects

Common adverse reactions include:

• Hypertension

• Fatigue

• Hand-foot skin reaction

• Diarrhea and nausea

• Proteinuria

• Elevated liver enzymes

Patients should be closely monitored, and supportive care should be provided to manage side effects.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions & Warnings

• Monitor blood pressure regularly due to the risk of hypertension

• Monitor liver and kidney function periodically

• Use caution in patients with cardiovascular disease or bleeding disorders

• Advise patients on sun protection, as photosensitivity reactions may occur

• Pregnancy and lactation: Anlotib may cause fetal harm; avoid use during pregnancy and breastfeeding

Use in Special Populations

• Renal impairment: No dose adjustment for mild or moderate renal impairment; caution in severe cases

• Hepatic impairment: Dose adjustment may be required for moderate to severe impairment

• Elderly patients: No significant differences observed, but monitor tolerability

Storage Conditions

Store below 30°C in a cool, dry place.
Protect from light and moisture.
Keep out of the reach of children.